Loss of RAGE defense: A cause of charcot neuroarthropathy?

Diabetes Care

Volumn 34, Issue 7, 2011, Pages 1617-1621

  Witzke, Kara A ^a   Vinik, Aaron I ^b   Grant, Lisa M ^b   Grant, William P ^c   Parson, Henri K ^b   Pittenger, Gary L ^b   Burcus, Niculina ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Tidewater Foot and Ankle Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; OSTEOCALCIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; AUTONOMIC NEUROPATHY; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOWN REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL STIFFNESS; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROPATHIC JOINT DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PROTEIN BLOOD LEVEL; UPREGULATION; BLOOD; BONE REMODELING; CROSS-SECTIONAL STUDY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; ARTHROPATHY, NEUROGENIC; BONE REMODELING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; OSTEOCALCIN; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC;

EID: 80054697001     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2315     Document Type: Article

References (25)

1. Sinha S, Munichoodappa CS, Kozak GP. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore) 1972;51:191-210
2. Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000;23:796-800 (Pubitemid 30414196)
3. Jeffcoate W. The causes of the Charcot syndrome. Clin Podiatr Med Surg 2008;25:29-42, vi (Pubitemid 350299818)
4. Mabilleau G, Edmonds ME. Role of neuropathy on fracture healing in Charcot neuro-osteoarthropathy. J Musculoskelet Neuronal Interact 2010;10:84-91
5. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008;51:1035-1040
6. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996;11:931-937 (Pubitemid 26200043)
7. Levin ME, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 1976;294:241-245
8. Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647-1658 (Pubitemid 41243553)
9. Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007;40:345-353 (Pubitemid 46054556)
10. Macaione V, Aguennouz M, Rodolico C, et al. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurol Scand 2007;115:115-121 (Pubitemid 46018547)
11. Yaturu S. Diabetes and skeletal health. J Diabetes 2009;1:246-254
12. Shapiro SA, Stansberry KB, Hill MA, et al. Normal blood flow response and vasomotion in the diabetic Charcot foot. J Diabetes Complications 1998;12:147-153 (Pubitemid 28241439)
13. Vashishth D. Advanced glycation end-products and bone fractures. IBMS Bone-Key 2009;6:268-278
14. Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg 1997;36:272-278; discussion 330
15. Witzke KA, Vinik AI. Diabetic neuropathy in older adults. Rev Endocr Metab Disord 2005;6:117-127 (Pubitemid 40603513)
16. Sanders L, Frykberg RG. Diabetic neuropathic osteoarthropathy. In The High Risk Foot in Diabetes Mellitus. Frykberg RG, Ed. New York, NY, Churchill Livingstone, 1991, p. 569
17. Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther 2001;3:29-50 (Pubitemid 32405675)
18. Vinik AI, Suwanwalaikorn S, Stansberry KB, Holland MT, McNitt PM, Colen LE. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995;18:574-584
19. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387-397 (Pubitemid 46148513)
20. Peel NF, Spittlehouse AJ, Bax DE, Eastell R. Bone mineral density of the hand in rheumatoid arthritis. Arthritis Rheum 1994;37:983-991 (Pubitemid 24222088)
21. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007;113:154-161 (Pubitemid 47547388)
22. McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Nonenzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001;2:16
23. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010;21:195-214
24. Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006;39:1073-1079 (Pubitemid 44528385)
25. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842-853